Moat
8.0/10
Major branded medicines, regulatory approvals, clinical evidence, patents, and commercial scale create a strong moat, though loss of exclusivity can sharply weaken individual franchises.
BMYQueued from the May 25, 2026 S&P 500 market-cap snapshot ranks 76-100.
Bristol Myers Squibb
Bristol Myers Squibb is a global biopharmaceutical company focused on oncology, hematology, immunology, cardiovascular disease, and neuroscience medicines.
Metadata
Where this company sits
- Ticker
- BMY
- Rank snapshot
- ≈ 88
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Region
- United States
- Index
- S&P 500 · Top 100 by market cap
Metrics
Scoring view
Every metric is paired with a short rationale. The numbers are deliberate, not divine.
Decentralizability
2.0/10
Approved pharmaceutical products require centralized regulated manufacturing, clinical validation, and pharmacovigilance; decentralization is more plausible in discovery, evidence networks, and post-exclusivity generic production.
Profitability
7.0/10
BMS reported substantial 2025 revenue and returned to positive annual earnings after acquisition-related losses in the prior year, though profitability remains exposed to product mix and patent-cycle transitions.
Price / Earnings
16.7x
StockAnalysis reported a trailing P/E ratio near 16.7 for BMY around the May 2026 market-data snapshot.
Market cap
$121.6B
StockAnalysis reported BMY market capitalization of about $121.61 billion as of May 21, 2026, close to the provided CompaniesMarketCap snapshot context.
Freed-up capital potential
$7.3B
Derived from market cap, moat resistance, decentralizability, and profitability. It is a directional estimate of value capture that could come under pressure if open alternatives compound.
Narrative
Why the company matters
A short editorial overview plus the current thesis on moat strength and decentralization pressure.
Business mix
Bristol Myers Squibb develops and commercializes branded medicines across several high-value therapeutic areas, with Eliquis and Opdivo among its largest products.
The 2025 revenue base was broad but still concentrated in major franchises, with Eliquis and Opdivo together representing a large share of reported product revenue.
Patent-cycle exposure
The company benefits from regulatory approvals, clinical evidence, prescribing relationships, and intellectual-property protection, but it also faces the standard pharmaceutical patent-cliff pattern as exclusivity expires.
BMS describes generic and biosimilar competition as a material business risk because sales of original branded medicines can decline quickly after loss of exclusivity.
Moat reading
Bristol Myers Squibb's moat is rooted in patents, regulatory exclusivity, clinical-trial evidence, physician familiarity, reimbursement access, and a large commercial organization. These advantages are strongest while exclusivity and label differentiation remain intact.
The moat is not permanent in the way a protocol or network standard might be. Once patent and regulatory barriers weaken, chemistry-based products can face rapid generic erosion, while biologics and immuno-oncology products remain harder to copy but still face competitive pressure from new mechanisms, combinations, and biosimilars.
Decentralization reading
Near-term decentralization is limited because drug development, manufacturing, pharmacovigilance, and regulatory approval are centralized and heavily controlled for patient-safety reasons.
The more credible decentralizing pressure comes upstream and downstream: open discovery tools, shared target data, transparent evidence generation, cooperative trial networks, and generic or biosimilar manufacturing once exclusivity expires. Those mechanisms can reduce dependence on a single originator without bypassing regulated quality systems.
Products
Where the moat actually touches users
These pages zoom into the products and services that matter most to each company, the alternatives already nibbling at them, and 2 structured disruption concepts across the current product set.
2 disruption concepts tracked0 documented exceptions
Technology waves
Strategic lenses
These are the repo's explicit bias terms: the technologies expected to keep making incumbents less inevitable over time.
Paper trail
Visible evidence trail
These sources shaped the scoring and writing. The site is opinionated, but it should not behave like it is improvising facts in a dark room.
Bristol Myers Squibb 2025 Annual Report
Bristol Myers Squibb · annual report
Primary company filing source for business description, risk factors, revenues, product portfolio, and profitability context.
Reviewed 2026-05-27
Bristol Myers Squibb Key Facts
Bristol Myers Squibb · investor relations
Company-maintained fact page summarizing 2025 product revenue, including Eliquis and Opdivo.
Reviewed 2026-05-27
Bristol-Myers Squibb Company Market Cap and Stock Overview
StockAnalysis · market data
Market-data source for May 2026 market capitalization and P/E ratio cross-check.
Reviewed 2026-05-27